Zika Virus Persistently Infects and Is Basolaterally Released from Primary Human Brain Microvascular Endothelial

Megan C Mladinich1,2, John Schwedes3, Erich R Mackow4,2

  • 1Department of Molecular Genetics and Microbiology, Stony Brook University, Stony Brook, New York, USA.

Mbio
|July 13, 2017
PubMed

Insights

Zika virus (ZIKV) persistently infects human brain endothelial cells, acting as a reservoir. This finding reveals new mechanisms for ZIKV persistence and spread across the blood-brain barrier.

Area of Science:

  • Virology
  • Neuroscience
  • Immunology

Background:

  • Zika virus (ZIKV) causes encephalitis and fetal microcephaly, persisting in bodily fluids and crossing critical barriers.
  • Mechanisms of ZIKV persistence and entry into neuronal compartments remain unclear.
  • Endothelial cells (ECs) form the blood-brain barrier (BBB), normally restricting pathogen access to neurons.

Purpose of the Study:

  • To investigate ZIKV's interaction with human brain microvascular ECs (hBMECs).
  • To elucidate mechanisms of ZIKV persistence and its potential to cross the BBB.
  • To identify novel targets for restricting ZIKV spread.

Main Methods:

  • Primary human brain microvascular ECs (hBMECs) were infected with ZIKV (strain PRVABC59).
  • Persistent replication, cytopathology, and barrier integrity were assessed.
  • Transcriptome analysis identified host responses to ZIKV infection.
  • Interferon (IFN) responses were evaluated.

Main Results:

  • ZIKV persistently replicated in hBMECs for over 9 days without causing cell damage.
  • ZIKV was released basolaterally from polarized hBMECs, suggesting BBB crossing.
  • Infected hBMECs showed resistance to IFN-α and altered IFN-β/λ secretion.
  • Transcriptome analysis revealed constitutive induction of IFN regulatory factors and IFN-stimulated genes (ISGs).

Conclusions:

  • hBMECs serve as a reservoir for persistent ZIKV replication.
  • ZIKV utilizes hBMECs to potentially cross the BBB and spread to neuronal compartments.
  • ZIKV employs novel persistence mechanisms, including evasion of antiviral responses, within hBMECs.
  • Targeting hBMEC responses may offer strategies to combat ZIKV persistence and spread.